ChiCTR1900023969 版本V1.0 版本创建时间2019/10/21 16:46:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900023969 

最近更新日期:

Date of Last Refreshed on:

2019-06-20 10:28:33 

注册时间:

Date of Registration:

2019-06-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

刘敏医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。 中国经直肠三维超声评估直肠癌分期及新辅助治疗后疗效的多中心、前瞻性临床研究

Public title:

Evaluation of preoperative staging and treatment response of rectal cancer after neoadjuvant chemoradiation by three-dimensional transrectal ultrasound——a multi-center prospective clinical study in China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中国经直肠三维超声评估直肠癌分期及新辅助疗效的多中心、前瞻性临床研究

Scientific title:

Evaluation of preoperative staging and treatment response of rectal cancer after neoadjuvant chemoradiation by three-dimensional transrectal ultrasound——a multi-center prospective clinical study in China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘敏 

研究负责人:

李安华 

Applicant:

Min Liu 

Study leader:

Li Anhua 

申请注册联系人电话:

Applicant telephone:

+86 020 87343441

研究负责人电话:

Study leader's telephone:

+86 020 87343211

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liumin@sysucc.org.cn

研究负责人电子邮件:

Study leader's E-mail:

liah@sysucc.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区东风东路651号

研究负责人通讯地址:

广东省广州市越秀区东风东路651号

Applicant address:

651 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong, China

Study leader's address:

651 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学肿瘤防治中心

Applicant's institution:

Department of Ultrasound, Sun Yat-Sen University Cancer Center

研究负责人所在单位:

中山大学肿瘤防治中心

Affiliation of the Leader:

Department of Ultrasound, Sun Yat-Sen University Cancer Center

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学肿瘤防治中心

Primary sponsor:

Sun Yat-Sen University Cancer Center

研究实施负责(组长)单位地址:

广东省广州市东风东路651号

Primary sponsor's address:

651 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

GuangDong

City:

GuangZhou

单位(医院):

中山大学肿瘤防治中心

具体地址:

越秀区东风东路651号

Institution
hospital:

Sun Yat-Sen University Cancer Center

Address:

651 Dongfeng Road East, Yuexiu District

经费或物资来源:

无资助

Source(s) of funding:

No found

Target disease:

Rectal Cancer

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

(一):经直肠三维超声评估直肠癌分期诊断效能,为直肠癌治疗前精准分期提供可靠数据参考。 (二):评价经直肠三维超声对于局部进展期直肠癌新辅助治疗后疗效评估的诊断效能,为直肠癌新辅助治疗后采用观察&等待策略或手术治疗的方法选择提供可靠依据。  

Objectives of Study:

(1) To evaluate the diagnostic efficacy of rectal cancer staging in three-dimensional transrectal ultrasound, which can provide reliable data reference for accurate staging of rectal cancer before treatment. (2) To evaluate the treatment response of locally advanced rectal cancer after neoadjuvant chemoradiation by three-dimensional transrectal ultrasound, and to provide a reliable basis for the selection of watch&wait strategy or surgical treatment methods after neoadjuvant therapy for rectal cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)治疗前活检病理证实为直肠腺癌;
2)未接受任何治疗的初诊患者;
3)拟在本院接受手术可获得病理;
4)治疗前均接受经直肠三维超声检查,且超声探头可完整探及病灶上缘(建议肿瘤位于距肛门10cm之内),图像资料完整;
5)了解并愿意签署知情同意书。

Inclusion criteria

1) Biopsy-proven primary rectal adenocarcinoma;
2)Initial patients without any treatment;
3)Pathology can be obtained by operation in our hospital.
4)All patients were examined by transrectal 3D ultrasound before treatment, and the upper edge of the lesion could be completely detected by ultrasound probe (it is suggested that the tumors should be located within 10 cm from the anus). The image data were complete.
5)Patients should understand and be willing to sign an informed consent form.

排除标准:

1)经直肠3D及MRI图像资料不完全或者图像质量差者;
2)或合并严重的慢性心脑血管、肝胆、肾脏疾病,以及其他恶性肿瘤或免疫缺陷疾病;已经存在或合并存在出血性疾病者;处于怀孕期或哺乳期的女性患者及其他不可控的不可手术者。

Exclusion criteria:

1) Incomplete or inferior image data of three-dimensional transrectal ultrasound pre- and post-neoadjuvant therapy.
2) Combined with severe chronic cardiovascular and cerebrovascular diseases, liver and gallbladder, kidney diseases, and other malignant tumors or immunodeficiency diseases; existing or combined with hemorrhagic diseases; pregnant or lactating women and other uncontrollable and inoperable patients.

研究实施时间:

Study execute time:

From 2019-06-25 00:00:00 To 2021-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-06-25 00:00:00 To 2020-12-31 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

病理,磁共振

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

pathology ,MRI

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

经直肠三维超声

Index test:

three-dimensional transrectal ultrasound

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

直肠癌腺癌

例数:

Sample size:

600

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patient with primary rectal adenocarcinoma

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

100

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

中山大学肿瘤防治中心 

单位级别:

三级甲等 

Institution
hospital:

Sun Yat-Sen University Cancer Center

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

遂宁市 

Country:

China 

Province:

Sichuan 

City:

Suining 

单位(医院):

遂宁市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Suining Central Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

德阳市 

Country:

China 

Province:

Sichuan 

City:

Deyang 

单位(医院):

德阳市人民医院 

单位级别:

三级甲等 

Institution
hospital:

People's Hospital of Deyang City

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

成都医学院第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of ChengDu Medical College

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Provincial People’s Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Cancer Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

重庆市 

市(区县):

沙坪坝区 

Country:

China 

Province:

Chongqing 

City:

Shapingba District 

单位(医院):

重庆肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

ChongQing University Cancer Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

绵阳市 

Country:

China 

Province:

Sichuan 

City:

Mianyang 

单位(医院):

绵阳市中心医院 

单位级别:

三级甲等 

Institution
hospital:

MianYang Central Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

云南省 

市(区县):

昆明市 

Country:

China 

Province:

Yunnan 

City:

Kunming 

单位(医院):

云南省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Yunnan Cancer Center

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

云南省 

市(区县):

昆明市 

Country:

China 

Province:

Yunnan 

City:

Kunming 

单位(医院):

昆明市中医医院 

单位级别:

三级甲等 

Institution
hospital:

Kunming Municipal Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

甘肃省 

市(区县):

兰州市 

Country:

China 

Province:

Gansu 

City:

Lanzhou 

单位(医院):

兰州大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Lanzhou University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

宁夏 

市(区县):

银川市 

Country:

China 

Province:

Ningxia 

City:

Yinchuan 

单位(医院):

宁夏医科大学总医院 

单位级别:

三级甲等 

Institution
hospital:

General Hospital of Ningxia Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

宁夏 

市(区县):

银川市 

Country:

China 

Province:

Ningxia 

City:

Yinchuan 

单位(医院):

宁夏自治区人民医院 

单位级别:

三级甲等 

Institution
hospital:

People's Hospital of Ningxia Hui Autonomous Region

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

上海市 

市(区县):

徐汇区 

Country:

China 

Province:

Shanghai 

City:

Xuhui District 

单位(医院):

复旦大学附属肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Fudan University Shanghai Cancer Center

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河南省 

市(区县):

郑州市 

Country:

China 

Province:

Henan 

City:

Zhengzhou 

单位(医院):

郑州市肿瘤医院 

单位级别:

三级医院 

Institution
hospital:

Zhengzhou Tumor Hospital

Level of the institution:

Tertiary Hospital

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

中山大学附属第六医院 

单位级别:

三级甲等 

Institution
hospital:

The Sixth Affiliated Hospital of Sun Yat-Sen University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广东 

市(区县):

湛江市 

Country:

China 

Province:

Guangdong 

City:

Zhanjiang 

单位(医院):

广东医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Guangdong Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China 

Province:

Guangodng 

City:

Guangzhou 

单位(医院):

广州医科大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

福建省 

市(区县):

福州市 

Country:

China 

Province:

Fujian 

City:

Fuzhou 

单位(医院):

福建省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Fujian Cancer Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

广西省 

市(区县):

南宁市 

Country:

China 

Province:

Guangxi 

City:

Nanning 

单位(医院):

广西医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Guangxi Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

山东省 

市(区县):

威海市 

Country:

China 

Province:

Shandong 

City:

 

单位(医院):

威海卫人民医院 

单位级别:

二级甲等 

Institution
hospital:

Weihaiwei People's Hospital

Level of the institution:

Secondary A Hospital

国家:

中国

省(直辖市):

湖北省 

市(区县):

武汉市 

Country:

China 

Province:

Hubei 

City:

Wuhan 

单位(医院):

武汉市第八人民医院 

单位级别:

三级医院 

Institution
hospital:

The Eighth Hospital of Wuhan

Level of the institution:

Tertiary Hospital

国家:

中国

省(直辖市):

新疆 

市(区县):

乌鲁木齐市 

Country:

China 

Province:

Xinjiang 

City:

Wulumuqi 

单位(医院):

新疆自治区人民医院 

单位级别:

三级甲等 

Institution
hospital:

Xinjiang Uiger Municipal People's Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河南省 

市(区县):

郑州市 

Country:

China 

Province:

Henan 

City:

Zhenzhou 

单位(医院):

河南省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Henan Cancer Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川省 

市(区县):

绵阳市 

Country:

China 

Province:

Sichuan 

City:

Mianyang 

单位(医院):

绵阳市第三人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Third People's Hospital of Mianyang

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

分期

指标类型:

主要指标

Outcome:

staging

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

完全缓解

指标类型:

次要指标

Outcome:

pathologic complete response

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, PPV, NPV, Kappa

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, PPV, NPV, Kappa

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肿瘤组织

组织:

直肠

Sample Name:

Tumor tissue

Tissue:

Rectal

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

淋巴结

组织:

Sample Name:

Lymph gland

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Research Data Deposit

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Research Data Deposit

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF及RDD

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF及RDD

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-06-20 10:28:33